Accuster Revenue and Competitors
Estimated Revenue & Valuation
- Accuster's estimated annual revenue is currently $109.3M per year.
- Accuster's estimated revenue per employee is $337,500
Employee Data
- Accuster has 324 Employees.
- Accuster grew their employee count by 4% last year.
Accuster's People
Name | Title | Email/Phone |
---|
Accuster Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $207.2M | 614 | 27% | N/A | N/A |
#2 | $101.6M | 301 | 8% | N/A | N/A |
#3 | $103.3M | 306 | 30% | N/A | N/A |
#4 | $157.6M | 467 | 5% | N/A | N/A |
#5 | $88.5M | 298 | 8% | N/A | N/A |
#6 | $188.6M | 550 | 17% | $13.2M | N/A |
#7 | $226.8M | 672 | -5% | N/A | N/A |
#8 | $368.2M | 974 | 20% | N/A | N/A |
#9 | $115.4M | 342 | 15% | N/A | N/A |
#10 | $356.1M | 942 | 4% | N/A | N/A |
What Is Accuster?
Accuster Technologies is on the way to become the global face of the in - vitro diagnosis and has revolutionized the conventional methods via novel out-breaking technology. Accuster is name synonymous to innovation and quality. We are engaged in offering an impeccable range of diagnosis products to the national and international client's at most competitive prices. Our entire range of Diagnosis Products manufactured with best quality components and conforms to CE, ISO and FIIT Certification. We have the World's First & Only Portable Biochemistry Lab and Many new innovations in the pipeline. This Project is being funded by Central Government & Approved by DSIR has patent across 60 countries in the world along with highest standard of technical competency & undreamed affordability.
keywords:N/AN/A
Total Funding
324
Number of Employees
$109.3M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $59.1M | 326 | 8% | N/A |
#2 | $104.1M | 333 | 35% | $3M |
#3 | $127.7M | 335 | 1% | N/A |
#4 | $88.5M | 337 | 23% | N/A |
#5 | $106.7M | 340 | 37% | N/A |